Aroniadis OC, Brandt LJ, Oneto C,
Feuerstadt P, Sherman A, Wolkoff AW, et al. Faecal microbiota transplantation
for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised,
placebo-controlled trial. Lancet Gastroenterol Hepatol 2019;4(9):675-85. https://www.ncbi.nlm.nih.gov/pubmed/31326345
Bae S, Lee KJ, Kim YS, Kim KN.
Determination of rifaximin treatment period according to lactulose breath test
values in nonconstipated irritable bowel syndrome subjects. J Korean Med Sci
2015;30(6):757-62. https://www.ncbi.nlm.nih.gov/pubmed/26028929
Basnayake C, Kamm MA, Stanley A,
Wilson-O'Brien A, Burrell K, Lees-Trinca I, et al. Standard gastroenterologist
versus multidisciplinary treatment for functional gastrointestinal disorders
(MANTRA): an open-label, single-centre, randomised controlled trial. Lancet
Gastroenterol Hepatol 2020;5(10):890-9. https://www.ncbi.nlm.nih.gov/pubmed/32679040
Drossman DA, Tack J, Ford AC, Szigethy
E, Tornblom H, Van Oudenhove L. Neuromodulators for Functional Gastrointestinal
Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team
Report. Gastroenterology 2018;154(4):1140-71 e1. https://www.ncbi.nlm.nih.gov/pubmed/29274869
El-Salhy M, Hatlebakk JG, Gilja OH,
Brathen Kristoffersen A, Hausken T. Efficacy of faecal microbiota
transplantation for patients with irritable bowel syndrome in a randomised,
double-blind, placebo-controlled study. Gut 2020;69(5):859-67. https://www.ncbi.nlm.nih.gov/pubmed/31852769
Fodor AA, Pimentel M, Chey WD, Lembo A,
Golden PL, Israel RJ, et al. Rifaximin is associated with modest, transient
decreases in multiple taxa in the gut microbiota of patients with
diarrhoea-predominant irritable bowel syndrome. Gut Microbes 2019;10(1):22-33.
https://www.ncbi.nlm.nih.gov/pubmed/29708822
Green JE, Davis JA, Berk M, Hair C,
Loughman A, Castle D, et al. Efficacy and safety of fecal microbiota
transplantation for the treatment of diseases other than Clostridium difficile
infection: a systematic review and meta-analysis. Gut Microbes 2020;12(1):1-25.
https://www.ncbi.nlm.nih.gov/pubmed/33345703
Gunn D, Garsed K, Lam C, Singh G,
Lingaya M, Wahl V, et al. Abnormalities of mucosal serotonin metabolism and
5-HT3 receptor subunit 3C polymorphism in irritable bowel syndrome with
diarrhoea predict responsiveness to ondansetron. Aliment Pharmacol Ther
2019;50(5):538-46. https://www.ncbi.nlm.nih.gov/pubmed/31342534
Halkjaer SI, Christensen AH, Lo BZS,
Browne PD, Gunther S, Hansen LH, et al. Faecal microbiota transplantation alters
gut microbiota in patients with irritable bowel syndrome: results from a
randomised, double-blind placebo-controlled study. Gut 2018;67(12):2107-15.
https://www.ncbi.nlm.nih.gov/pubmed/29980607
Hugerth LW, Andreasson A, Talley NJ,
Forsberg AM, Kjellstrom L, Schmidt PT, et al. No distinct microbiome signature
of irritable bowel syndrome found in a Swedish random population. Gut
2020;69(6):1076-84. https://www.ncbi.nlm.nih.gov/pubmed/31601615
Ianiro G, Eusebi LH, Black CJ,
Gasbarrini A, Cammarota G, Ford AC. Systematic review with meta-analysis:
efficacy of faecal microbiota transplantation for the treatment of irritable
bowel syndrome. Aliment Pharmacol Ther 2019;50(3):240-8. https://www.ncbi.nlm.nih.gov/pubmed/31136009
Johnsen PH, Hilpusch F, Valle PC, Goll
R. The effect of fecal microbiota transplantation on IBS related quality of life
and fatigue in moderate to severe non-constipated irritable bowel: Secondary
endpoints of a double blind, randomized, placebo-controlled trial. EBioMedicine
2020;51:102562. https://www.ncbi.nlm.nih.gov/pubmed/31877418
Lacy BE, Pimentel M, Brenner DM, Chey
WD, Keefer LA, Long MD, et al. ACG clinical guideline: Management of irritable
bowel syndrome. Am J Gastroenterol 2021;116(1):17-44. https://www.ncbi.nlm.nih.gov/pubmed/33315591
Lahtinen P, Jalanka J, Hartikainen A,
Mattila E, Hillila M, Punkkinen J, et al. Randomised clinical trial: faecal
microbiota transplantation versus autologous placebo administered via
colonoscopy in irritable bowel syndrome. Aliment Pharmacol Ther
2020;51(12):1321-31. https://www.ncbi.nlm.nih.gov/pubmed/32343000
Lembo A, Pimentel M, Rao SS, Schoenfeld
P, Cash B, Weinstock LB, et al. Repeat treatment with rifaximin is safe and
effective in patients with diarrhea-predominant irritable bowel syndrome.
Gastroenterology 2016;151(6):1113-21. https://www.ncbi.nlm.nih.gov/pubmed/27528177
Li J, Zhu W, Liu W, Wu Y, Wu B.
Rifaximin for irritable bowel syndrome: a meta-analysis of randomized
placebo-controlled trials. Medicine (Baltimore) 2016;95(4):e2534. https://www.ncbi.nlm.nih.gov/pubmed/26825893
Major G, Pritchard S, Murray K,
Alappadan JP, Hoad CL, Marciani L, et al. Colon Hypersensitivity to Distension,
Rather Than Excessive Gas Production, Produces Carbohydrate-Related Symptoms in
Individuals With Irritable Bowel Syndrome. Gastroenterology 2017;152(1):124-33
e2. https://www.ncbi.nlm.nih.gov/pubmed/27746233
Moayyedi P, Andrews CN, MacQueen G,
Korownyk C, Marsiglio M, Graff L, et al. Canadian Association of
Gastroenterology clinical practice guideline for the management of irritable
bowel syndrome (IBS). J Can Assoc Gastroenterol 2019;2(1):6-29. https://www.ncbi.nlm.nih.gov/pubmed/31294724
Myneedu K, Deoker A, Schmulson MJ,
Bashashati M. Fecal microbiota transplantation in irritable bowel syndrome: a
systematic review and meta-analysis. United European Gastroenterol J
2019;7(8):1033-41. https://www.ncbi.nlm.nih.gov/pubmed/31662860
Pimentel M, Cash BD, Lembo A, Wolf RA,
Israel RJ, Schoenfeld P. Repeat rifaximin for irritable bowel syndrome: no
clinically significant changes in stool microbial antibiotic sensitivity. Dig
Dis Sci 2017;62(9):2455-63. https://www.ncbi.nlm.nih.gov/pubmed/28589238
Pimentel M, Lembo A, Chey WD, Zakko S,
Ringel Y, Yu J, et al. Rifaximin therapy for patients with irritable bowel
syndrome without constipation. N Engl J Med 2011;364(1):22-32. https://www.ncbi.nlm.nih.gov/pubmed/21208106
Plasse TF, Barton G, Davidson E,
Abramson D, Kalfus I, Fathi R, et al. Bimodal release ondansetron improves stool
consistency and symptomatology in diarrhea-predominant irritable bowel syndrome:
a randomized, double-blind, trial. Am J Gastroenterol 2020;115(9):1466-73. https://www.ncbi.nlm.nih.gov/pubmed/32639235
Xu D, Chen VL, Steiner CA, Berinstein
JA, Eswaran S, Waljee AK, et al. Efficacy of fecal microbiota transplantation in
irritable bowel syndrome: a systematic review and meta-analysis. Am J
Gastroenterol 2019;114(7):1043-50. https://www.ncbi.nlm.nih.gov/pubmed/30908299
Zheng Y, Yu T, Tang Y, Xiong W, Shen X,
Jiang L, et al. Efficacy and safety of 5-hydroxytryptamine 3 receptor
antagonists in irritable bowel syndrome: A systematic review and meta-analysis
of randomized controlled trials. PLoS One 2017;12(3):e0172846. https://www.ncbi.nlm.nih.gov/pubmed/28291778
